{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.647","upperLimit":"0.859","value":"0.773"},{"groupId":"OG001","lowerLimit":"0.527","upperLimit":"0.833","value":"0.711"}]}],"title":"6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.407","upperLimit":"0.667","value":"0.547"},{"groupId":"OG001","lowerLimit":"0.290","upperLimit":"0.633","value":"0.471"}]}],"title":"1 Year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.265","upperLimit":"0.537","value":"0.403"},{"groupId":"OG001","lowerLimit":"0.127","upperLimit":"0.467","value":"0.286"}]}],"title":"2 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Probability of survival was calculated from the product-limit method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"OG000","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"OG001","title":"Part 2: PF-06801591 300 mg (SC) for UC"}],"paramType":"NUMBER","populationDescription":"Analysis population included all the randomized participants who received PF-06801591 and had at least 1 post-dose concentration measurement above the lower limit of quantification (LLQ).","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment in Part 2 (maximum of 851 days)","title":"Probability of Survival at 6 Months, 1 Year, and 2 Years - Part 2","type":"SECONDARY","unitOfMeasure":"Probability"}